[go: up one dir, main page]

MX381239B - Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr). - Google Patents

Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr).

Info

Publication number
MX381239B
MX381239B MX2017006567A MX2017006567A MX381239B MX 381239 B MX381239 B MX 381239B MX 2017006567 A MX2017006567 A MX 2017006567A MX 2017006567 A MX2017006567 A MX 2017006567A MX 381239 B MX381239 B MX 381239B
Authority
MX
Mexico
Prior art keywords
farnesoid
fxr
receptor
alpha
alkyl
Prior art date
Application number
MX2017006567A
Other languages
English (en)
Other versions
MX2017006567A (es
Inventor
Alexander Weymouth-Wilson
Carl Otter
Ieuan Davies
James Boydell
Laura Wallis
Rob Clarkson
Zofia Komsta
Original Assignee
Nzp Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1420594.2A external-priority patent/GB201420594D0/en
Priority claimed from GBGB1420593.4A external-priority patent/GB201420593D0/en
Priority claimed from GBGB1505675.7A external-priority patent/GB201505675D0/en
Application filed by Nzp Uk Ltd filed Critical Nzp Uk Ltd
Publication of MX2017006567A publication Critical patent/MX2017006567A/es
Publication of MX381239B publication Critical patent/MX381239B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a compuestos de la fórmula (I), en donde R1, R2, Y, R4 y R5b son como se definen aquí; los compuestos son intermedios en la síntesis de ácidos biliares sintéticos. (ver Fórmula).
MX2017006567A 2014-11-19 2015-11-19 Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr). MX381239B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1420594.2A GB201420594D0 (en) 2014-11-19 2014-11-19 Compounds
GBGB1420593.4A GB201420593D0 (en) 2014-11-19 2014-11-19 Compounds
GBGB1505675.7A GB201505675D0 (en) 2015-04-01 2015-04-01 Compounds
PCT/GB2015/053519 WO2016079520A1 (en) 2014-11-19 2015-11-19 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators

Publications (2)

Publication Number Publication Date
MX2017006567A MX2017006567A (es) 2018-01-26
MX381239B true MX381239B (es) 2025-03-12

Family

ID=54704022

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006567A MX381239B (es) 2014-11-19 2015-11-19 Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr).

Country Status (11)

Country Link
US (2) US20170327531A1 (es)
EP (1) EP3221334B1 (es)
JP (1) JP6698085B2 (es)
KR (1) KR102527821B1 (es)
CN (1) CN107207558B (es)
CA (1) CA2968310A1 (es)
EA (1) EA033603B1 (es)
HK (1) HK1244286A1 (es)
MX (1) MX381239B (es)
TW (1) TWI688571B (es)
WO (1) WO2016079520A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6724004B2 (ja) 2014-11-19 2020-07-15 エヌゼットピー ユーケー リミテッド ステロイドＦＸＲモジュレーター製造のための中間体としての５β−６−アルキル−７−ヒドロキシ−３−オンステロイド
MX381239B (es) 2014-11-19 2025-03-12 Nzp Uk Ltd Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr).
BR112017010319B1 (pt) 2014-11-19 2023-04-11 NZP UK Limited Esteroides 6-alquil-7-hidróxi-4-en-3-ona e processo para a preparação dos mesmos
CA2968305A1 (en) 2014-11-19 2016-05-26 NZP UK Limited 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators
JP2018538331A (ja) * 2015-12-22 2018-12-27 インターセプト ファーマシューティカルズ， インコーポレイテッド オベチコール酸の多型結晶形態
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608779D0 (en) * 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
CN106046093A (zh) * 2016-05-30 2016-10-26 华东师范大学 一种石胆酸的合成方法
EP3431486A1 (en) 2017-07-18 2019-01-23 Bionice, S.L.U. Process and intermediates for the synthesis of obeticholic acid and derivatives thereof
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN111285914B (zh) * 2018-12-10 2023-02-17 江西青峰药业有限公司 一种奥贝胆酸的制备方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2624748A (en) 1950-09-09 1953-01-06 Upjohn Co Bisnorchola-4, 6-dien-3-one-22-al
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
EP0636156B1 (en) 1992-04-14 1997-07-30 Cornell Research Foundation, Inc. Dendritic based macromolecules and method of production
WO1994019366A1 (en) 1993-02-26 1994-09-01 Magainin Pharmaceuticals Inc. Chemical synthesis of squalamine
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
IL157816A0 (en) 2001-03-12 2004-03-28 Roberto Pellicciari Steroids as agonists for fxr
US20090062256A1 (en) 2001-06-01 2009-03-05 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
CA2466027C (en) 2001-11-07 2013-01-08 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
JP2007210888A (ja) 2006-01-12 2007-08-23 Mitsubishi Chemicals Corp ステロイド化合物の製造方法
CN101395170A (zh) 2006-02-14 2009-03-25 英特塞普特药品公司 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物
US7932244B2 (en) 2006-06-27 2011-04-26 Intercept Pharmaceuticals, Inc. Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
EA017714B1 (ru) 2007-01-19 2013-02-28 Интерсепт Фармасьютикалз, Инк. Модуляторы tgr5 и способы их применения
EA020310B1 (ru) 2008-07-30 2014-10-30 Интерсепт Фармасьютикалз, Инк. Модуляторы рецептора tgr5 и их применение
EP3150620B1 (en) 2008-11-19 2020-01-08 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
AU2009316566B9 (en) 2008-11-19 2014-05-15 Intercept Pharmaceuticals, Inc. TGR5 modulators and method of use thereof
CA2769203A1 (en) 2009-07-29 2011-02-03 University Of Chicago Liver x receptor agonists
KR20190121871A (ko) 2012-06-19 2019-10-28 인터셉트 파마슈티컬즈, 인크. 오베티콜산의 제조법, 용도 및 고체 형태
EP2912013B1 (en) 2012-10-26 2017-10-11 Intercept Pharmaceuticals, Inc. Process for preparing bile acid derivatives
CA2891348C (en) * 2012-11-28 2020-04-28 Intercept Pharmaceuticals, Inc. Treatment of pulmonary disease
US20140206657A1 (en) * 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists
CN108245523B (zh) 2013-05-14 2021-03-26 英特塞普特医药品公司 作为法尼醇x受体调节剂的胆汁酸的11-羟基衍生物及其氨基酸共轭物
SG11201509370UA (en) 2013-05-24 2015-12-30 Nestec Sa Pathway specific assays for predicting irritable bowel syndrome diagnosis
US10166246B2 (en) * 2014-05-27 2019-01-01 City Of Hope TGR5 agonist complexes for treating diabetes and cancer
LT3626725T (lt) 2014-05-29 2023-03-10 Bar Pharmaceuticals S.R.L. Cholano dariniai skirti naudoti ligų, kurių atsiradimui tarpininkauja fxr ir tgr5/gpbar1, gydymui ir (arba) profilaktikai
KR20170094184A (ko) 2014-11-06 2017-08-17 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
BR112017010319B1 (pt) 2014-11-19 2023-04-11 NZP UK Limited Esteroides 6-alquil-7-hidróxi-4-en-3-ona e processo para a preparação dos mesmos
MX381239B (es) 2014-11-19 2025-03-12 Nzp Uk Ltd Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr).
CA2968305A1 (en) 2014-11-19 2016-05-26 NZP UK Limited 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators
JP6724004B2 (ja) 2014-11-19 2020-07-15 エヌゼットピー ユーケー リミテッド ステロイドＦＸＲモジュレーター製造のための中間体としての５β−６−アルキル−７−ヒドロキシ−３−オンステロイド
WO2016086134A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
MX2017006833A (es) 2014-11-26 2018-02-13 Enanta Pharm Inc Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
CN106279328A (zh) 2015-05-20 2017-01-04 重庆药友制药有限责任公司 一种制备6α-烷基鹅去氧胆酸的方法
SI3310801T1 (sl) 2015-06-19 2021-10-29 Intercept Pharmaceuticals Inc Modulatorji TGR5 in postopki za uporabo le-teh
CN106397522A (zh) 2015-07-31 2017-02-15 中国人民解放军军事医学科学院毒物药物研究所 3,7‑二（叔丁基二甲基硅基氧基）‑6‑烯‑5β‑胆烷‑24‑酸甲酯
CN106478759A (zh) 2015-08-31 2017-03-08 陕西合成药业股份有限公司 奥贝胆酸衍生物及其制备方法和用途
CN106478756A (zh) 2015-09-02 2017-03-08 中美华世通生物医药科技（武汉）有限公司 Oca-e单晶及其制备方法和用途
CN106518946A (zh) 2015-09-10 2017-03-22 上海迪诺医药科技有限公司 磺酰脲衍生物、其药物组合物及应用

Also Published As

Publication number Publication date
TW201632539A (zh) 2016-09-16
EP3221334A1 (en) 2017-09-27
JP6698085B2 (ja) 2020-05-27
KR20170099896A (ko) 2017-09-01
WO2016079520A1 (en) 2016-05-26
JP2017534669A (ja) 2017-11-24
US20170327531A1 (en) 2017-11-16
EA201790885A1 (ru) 2017-11-30
MX2017006567A (es) 2018-01-26
US10597423B2 (en) 2020-03-24
CN107207558B (zh) 2019-10-29
US20190077827A1 (en) 2019-03-14
KR102527821B1 (ko) 2023-05-02
CN107207558A (zh) 2017-09-26
TWI688571B (zh) 2020-03-21
HK1244286A1 (zh) 2018-08-03
EA033603B1 (ru) 2019-11-08
EP3221334B1 (en) 2020-02-19
CA2968310A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
MX381239B (es) Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr).
MX375863B (es) Esteroides de 6-alquil-7-hidroxi-4-en-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr)
MX375865B (es) Esteroides de 6.alfa-alquil-3,7-diona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr).
MX375864B (es) Esteroides de 5.beta-6-alquil-7-hidroxi-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr)
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
NZ726859A (en) Synthesis of polycyclic-carbamoylpyridone compounds
CO2017001884A2 (es) Polimorfos de selinexor
DOP2015000054A (es) Derivados de c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
UY34472A (es) Derivados modificados de 4-fenil-piridina
FR3024465B1 (fr) Caracterisation de micro-organismes par maldi-tof
MX2017005578A (es) Métodos de administración de composiciones de amantadina.
ECSP16074207A (es) Pirazinas moduladoras de gpr6
CR20180426A (es) Profarmacos del moculador selectivo del receptor de la progesterona (msrp) (11.beta., 17.beta)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona
UY34457A (es) Composición de Nitazoxanida mejorada y proceso para prepararla
UY34489A (es) Derivados del ácido cicloalcanocarboxílico como antagonistas del receptor CXCR3
UY34819A (es) Derivados de ß-aminoácido sustituidos como antagonistas del receptor CXCR3.
IN2014MU00171A (es)